COMMUNIQUÉS West-GlobeNewswire

Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
26/02/2026
RADNOR, Pa., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities [...]
Anteris Reports 2025 Financial Results and Provides Corporate Update
27/02/2026
MINNEAPOLIS and BRISBANE, Australia, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (“Anteris” or the “Company”) (NASDAQ: AVR, ASX: AVR), a global structural heart company committed to designing, [...]
Alignment Healthcare Reports Fourth Quarter and Full-Year 2025 Results; Beats High-End of Guidance Across All Key Metrics
26/02/2026
Delivers full-year revenue of $3.95 billion, representing 46.1% growth year-over-year Exceeds high-end of fourth quarter and full-year guidance across all key metrics: membership, revenue, adjusted gross profit and [...]
DeepHealth Achieves CE Mark for TechLive™ and Enables AWS Marketplace Deployment, Advancing Global Expansion of Multimodality Vendor-Agnostic Remote Scanning Solution
26/02/2026
SOMERVILLE, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) -- DeepHealth, Inc., a global leader in AI-powered health informatics and a wholly owned subsidiary of RadNet, Inc. (NASDAQ: RDNT), today announced that TechLive™, its [...]
Galectin Therapeutics to Host Virtual KOL Event to Discuss Belapectin Development Program for Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) Cirrhosis and Portal Hypertension, on March 10, 2026 at 12:00 PM ET
26/02/2026
NORCROSS, Ga., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of galectin-3-targeted therapeutics for patients with MASH cirrhosis and portal hypertension, today [...]
The Kidney Foundation of Canada highlights need for Canadians to act on kidney health
26/02/2026
Take Action This Kidney Health Month and Ahead of World Kidney Day 2026 MONTREAL, Feb. 26, 2026 (GLOBE NEWSWIRE) -- As Kidney Health Month gets underway, The Kidney Foundation of Canada is calling on Canadians to take [...]
Tectonic Therapeutic Announces Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights
26/02/2026
Announced positive topline results from TX45 Phase 1b acute hemodynamic clinical trial in patients with Group 2 Pulmonary Hypertension in Heart Failure with reduced Ejection Fraction (“PH-HFrEF”) in October 2025. [...]
Organogenesis Holdings Inc. Reports Fourth Quarter 2025 Financial Results, Posts Record Revenue
26/02/2026
CANTON, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine and tissue innovations company focused on empowering healing through the development, [...]
Herz P1 Smart Ring in 2026: Features, Pricing, Accuracy Context, and What Consumers Should Verify Before Buying
27/02/2026
Examining the Herz P1 Smart Ring's Consumer Wearable Category for 2026: 24/7 Heart Rate Monitoring, Sleep Tracking, Stress and HRV Analysis, Activity Metrics, Smart Ring Pricing From $49.99 Per Unit, No Subscription [...]
Ryoncil® Profits Underpinning Substantial Growth Pipeline
27/02/2026
Financial Results and Operational Update for Half-Year Ended December 31, 2025 NEW YORK, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for [...]
UPDATE - Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of Sciometrix and its Digital Care Management Platform Clinicus
26/02/2026
WARREN, N.J. and ROYAL OAK, Mich., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN ) today announced that it has entered into a signed, non-exclusive, non-binding Letter of Intent [...]
Emergent BioSolutions Reports Fourth Quarter and Full Year 2025 Financial Results
26/02/2026
Fourth Quarter 2025 Total Revenues of $148.7 million; Full Year 2025 Total Revenues of $742.9 million Fourth Quarter 2025 Net Loss of $54.6 million and Net Loss Margin of 37% Full Year 2025 Net Income of $52.6 million [...]
Sprout Health NAD+ Injections — Compounding Status, Pharmacy Sourcing, and What Consumers Should Verify Before Any Telehealth NAD+ Enrollment in 2026
27/02/2026
Compounded NAD+ Telehealth Access, FDA Classification, Pharmacy Sourcing Standards, Prescription Requirements, and Consumer Verification Steps for Evaluating Any NAD+ Injection Program in 2026 Encinitas, CA, Feb. 26, [...]
Syndax Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
26/02/2026
– Total revenue of $68.7 million in 4Q25 and $172.4 million in FY2025 – – Revuforj ® (revumenib) net revenue of $44.2 million in 4Q25, a 38% increase vs 3Q25, and $124.8 million in FY2025 – – Niktimvo™ (axatilimab-csfr [...]
Relay Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Outlines Anticipated 2026 Milestones
26/02/2026
Initial Phase 1 data of zovegalisib in PIK3CA-driven vascular anomalies expected to be announced in first half of 2026 Breast cancer triplet data and frontline Phase 3 plans expected to be announced in 2026 Initial [...]
Tarsus to Participate in Upcoming Investor Conferences
26/02/2026
IRVINE, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that management plans to participate in the following upcoming investor conferences: TD Cowen 46 th Annual [...]
OrthoPediatrics Corp. Reports Fourth Quarter and Full Year 2025 Financial Results
26/02/2026
Record full year 2025 revenue of $236.3 million increased 15% compared to prior year Operating Cash flow improvement of $22 million in full year 2025 Generated $10 million of free cash flow in the fourth quarter, the [...]
Extendicare Announces 2025 Fourth Quarter and Full Year Results and Dividend Increase
26/02/2026
MARKHAM, Ontario, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Extendicare Inc. (“Extendicare” or the “Company”) (TSX: EXE) today reported results for the three and twelve months ended December 31, 2025. Fourth Quarter 2025 [...]
Clover Health Reports Fourth Quarter & Full Year 2025 Results; Provides Full Year 2026 Guidance
26/02/2026
Business Highlights: Generated full year 2025 Adjusted EBITDA profitability while growing membership by 38% and Insurance revenue by 41% year-over-year Achieved industry-leading 2026 AEP growth of 53% year-over-year [...]

Pages